Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?
The Archetypal Orphan Drug Biotech Company Remains Loss-Making
Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.